FluoGuide publishes interim report for Q1 2026
The report details FDA IND authorization and Fast Track Designation for FG001, and progress in head and neck cancer program.
See the latest news and media coverage for FluoGuide. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing fluorescent cancer surgery drugs
fluoguide.comLast updated
In short: FluoGuide achieved significant regulatory milestones for FG001, including FDA Fast Track Designation and IND clearance for high-grade glioma trials.
The report details FDA IND authorization and Fast Track Designation for FG001, and progress in head and neck cancer program.
Dr. Jane Skjøth-Rasmussen shared data at Brain Tumor Symposium 2026 in Copenhagen, highlighting FG001's potential to improve tumor delineation in meningioma and low-grade glioma surgery.
Interim data show 100% sensitivity in meningioma surgery and encouraging fluorescence in low-grade glioma. Presented at SNOG 2026.
The meeting adopts the 2025 annual report, re-elects board members, elects new member Kim D. Kjøller, authorizes warrants, updates articles of association, and approves board remuneration.
Visit a quote page and your recently viewed tickers will be displayed here.
Review the current valuation for FluoGuide AS Ordinary Shares (FLUO:XSTO) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company...
Copenhagen, Denmark, 10 April 2026 - FluoGuide A/S ("FluoGuide" or the "Company"), a clinical-stage biotech company maximizing surgical outcomes in oncology by lighting up cancer...
COPENHAGEN, DENMARK / ACCESS Newswire / March 18, 2026 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company maximizing surgical outcomes in oncology...
Track FluoGuide and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.